Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin
Table 3
Association of seropositivity to cutaneous human papillomavirus (HPV) types at the time of the diagnosis of index SCC and risk of subsequent squamous cell carcinoma (SCC) of the skin.
Viral infection at the time of the index SCC diagnosis
No subsequent SCC () (%)
Subsequent SCC ) (%)
HR
Any cutaneous
Seronegative to 33 cutaneous HPV types
6 (10.2)
9 (9.9)
1.00
Seropositive to ≥1 cutaneous HPV
53 (89.8)
82 (90.1)
0.83 (0.41–1.67)
Alpha cutaneous HPV
Seronegative to 33 cutaneous HPV types
6 (21.4)
9 (20.4)
1.00
Alpha HPV
22 (78.6)
35 (79.6)
0.86 (0.40–1.82)
Alpha HPV seronegative
37 (62.7)
56 (61.5)
Alpha HPV
22 (37.3)
35 (38.5)
1.04 (0.68–1.59)
Beta HPV
Seronegative to 33 cutaneous HPV types
6 (12.0)
9 (12.0)
1.00
Beta HPV
44 (88.0)
66 (88.0)
0.80 (0.39–1.62)
Beta HPV seronegative
15 (25.4)
25 (27.5)
1.00
Beta HPV
44 (74.6)
66 (72.5)
0.82 (0.51–1.30)
Any beta 1
Seronegative
6 (17.6)
9 (16.4)
1.00
Beta 1 HPV seropositive
28 (82.3)
46 (83.6)
0.77 (0.37–1.59)
Any beta 2
Seronegative
6 (17.6)
9 (15.0)
1.00
Beta 2 HPV seropositive
28 (82.3)
51 (85.0)
0.99 (0.48–2.04)
Multiple beta 1
Seronegative
18 (52.9)
24 (43.6)
1.00
Seropositive to ≥2 beta 1 HPV
16 (47.1)
31 (56.4)
1.06 (0.61–1.83)
Multiple beta 2
Seronegative
18 (52.9)
25 (41.7)
1.00
Seropositive to ≥2 beta 2 HPV
16 (47.1)
35 (58.3)
0.98 (0.58–1.67)
Gamma HPV
Seronegative to 33 cutaneous HPV types
6 (15.0)
9 (13.2)
1.00
34 (85.0)
59 (86.8)
0.93 (0.46–1.90)
Gamma HPV Seronegative
25 (42.4)
32 (35.2)
1.00
34 (57.6)
59 (64.8)
1.21 (0.78–1.87)
Mu HPV
Seronegative to 33 cutaneous HPV types
6 (22.2)
9 (20.5)
1.00
21 (77.8)
35 (79.5)
0.78 (0.37–1.65)
Mu HPV seronegative
38 (64.4)
56 (61.5)
1.00
21 (35.6)
35 (38.5)
1.05 (0.68–1.61)
Nu HPV
Seronegative to 33 cutaneous HPV types
6 (66.7)
9 (39.1)
1.00
3 (33.3)
14 (60.9)
0.96 (0.38–2.44)
Nu HPV seronegative
56 (94.9)
77 (84.6)
1.00
3 (5.1)
14 (15.4)
1.31 (0.73–2.34)
to any cutaneous HPV ( types) versus negative to all. to at least one genus specific type versus negative to all cutaneous () types. to at least one genus specific HPV versus seronegative to all genus-specific HPV types. to at least one beta 1 type versus seronegative to 33 cutaneous HPV types. to at least one beta 2 type versus seronegative to 33 cutaneous HPV types. to ≥2 beta 1 HPV types versus seronegative to all cutaneous types or positive to at least one beta 1 HPV type. to ≥2 beta 2 HPV types versus seronegative to all cutaneous types or positive to at least one beta 2 HPV type. HR = hazards ratio, CI = confidence interval. for age and gender.
